Abbott, Mylan back generics deal, tweak terms after tax rule change
October 22, 2014 at 09:24 AM EDT
Oct 22 (Reuters) - Abbott Laboratories and Mylan Inc on Wednesday said they would go ahead with their $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and set up headquarters in the Netherlands, but they tweaked the terms of the transaction.
